查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840670

混合成像市場按技術類型、銷售管道、應用和最終用戶分類 - 全球預測 2025-2032

Hybrid Imaging Market by Technology Type, Sales Channel, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，混合成像市場規模將達到 137.2 億美元，年複合成長率為 6.88%。

主要市場統計數據
基準年 2024 80.5億美元
預計年份：2025年 86億美元
預測年份：2032年 137.2億美元
複合年成長率 (%) 6.88%

權威的混合成像環境介紹重點闡述了臨床促進因素、技術融合以及醫療保健相關人員的策略重點。

混合影像技術融合了多種技術，契合了不斷變化的臨床需求和醫療體系發展趨勢。近年來，臨床醫生和技術開發人員致力於整合解剖成像和分子影像技術，以提高診斷特異性和治療監測效果，並專注於以患者為中心的工作流程和精準醫療。本應用綜述概述了關鍵促進因素、相關人員的期望以及決策者在評估混合成像技術發展現狀時應優先考慮的策略問題。

推動技術應用的因素包括：對複雜適應症診斷信心的提升、影像處理實驗室運作效率的提高，以及為獲得可量化結果以支持醫保報銷而進行的必要性評估。同時，檢測器設計、影像融合和放射性藥物研發的技術創新也催生了新的臨床應用情境。因此，醫療機構正從一次性投資的角度，著眼於長期臨床項目，重新評估其資本購買策略。

臨床醫生和管理人員必須權衡資本投入與潛在收益，例如提高診斷效率、減少後續處理以及改善患者管理。因此，他們必須考慮整合臨床路徑、供應商合作、培訓計劃等策略，以確保混合影像資產在整體醫療保健領域創造永續的價值。

技術整合、監管調整和供應鏈調整如何重新定義混合成像技術對醫療服務提供者和製造商的價值提案

在技​​術融合、監管環境演變和醫療服務模式變革的驅動下，混合成像領域正經歷著一場變革。近年來，結合功能和結構影像以提供更豐富診斷資訊的混合成像技術日益成熟，影像處理和人工智慧軟體的進步也開始提升診斷的可靠性和工作流程效率。與這些技術發展同步，法律規範和支付方政策也根據混合檢測中湧現的證據進行調整，鼓勵製造商和臨床研究人員設計能夠展現有意義臨床終點的檢測方法。

供應鏈重組和組件籌資策略正在重塑採購和製造決策，促進模組化設計，並加強系統整合商和放射性藥物供應商之間的合作。臨床實踐也在不斷發展，分子特徵如今已成為治療方案指南因素，尤其是在腫瘤學和神經病學領域。這些轉變並非漸進式的，而是系統性的，它們重新定義了價值提案，從純粹以硬體為中心轉向包含儀器、示踪劑、分析和服務模式的整合式臨床解決方案。

評估2025年關稅調整對混合成像價值鏈的採購、服務連續性和總擁有成本的累積影響

影響跨境貿易和零件關稅的政策變化，物流的製造商、經銷商和醫療保健系統帶來了新的考慮。 2025年關稅調整的累積影響正在改變核心子系統、外圍組件和放射性藥物物流的成本結構，迫使相關人員重新評估籌資策略和供應商合約條款。為此，許多醫療保健機構正在探索近岸外包、供應商多元化和長期採購協議等方式，以降低未來貿易政策波動帶來的風險。

臨床醫生和醫院財務團隊間接受到設備交付速度減慢和更換零件交貨前置作業時間延長的影響；分銷商和服務供應商必須重新評估保固和服務水準協議以適應不斷變化的成本基礎；製造商正在重新評估其全球生產佈局，以在不損害監管合規性或品管的情況下保護淨利率。

重要的是，關稅驅動的環境加速了關於整體擁有成本的討論，強調維護、培訓和臨床應用是維持價值的關鍵槓桿。對於專注於長期專案的相關人員而言，短期措施帶來的成本壓力凸顯了合約彈性、協作的供應關係和情境規劃對於維持醫療服務和技術部署連續性的重要性。

深入的細分洞察揭示了技術類型、銷售管道、臨床應用和最終用戶畫像如何決定混合成像技術的採用和價值實現。

對市場區隔的深入理解有助於明確臨床需求、採購管道和技術偏好之間的交集，從而塑造商業化和部署策略。在評估技術類型時，臨床醫師和管理者會區分PET-CT、PET-MRI和SPECT-CT，每種技術在敏感度、軟組織對比和操作空間方面都各具優勢。銷售管道也至關重要。選擇直銷協議或經銷商關係會影響合約的靈活性、售後支援和地理覆蓋範圍，進而影響服務內容和培訓計畫。

以應用為導向的細分揭示了診斷優先順序如何驅動成像方式的選擇和方案的發展。心臟病學應用，包括心肌灌注和活力檢測，需要穩定的定量性能和簡化的工作流程來支持高通量心臟計畫。感染疾病影像分為感染部位影像和發炎影像，需要靈活的示蹤劑選擇和快速的影像時間，以指導急診治療決策。神經病學應用，例如癲癇和神經退化評估，受益於高解析度分子定位和標準化的解讀框架。腫瘤學實踐涵蓋骨髓惡性腫瘤和固態腫瘤，高度依賴準確的分期和療效評估來最佳化治療順序。

診斷中心通常優先考慮吞吐量和發表網路，醫院強調整合式診療路徑和多學科協作，而研發則強調方案的靈活性和示踪劑的開發。了解這些維度之間的相互作用，有助於制定商業策略，從而根據每個細分市場的獨特需求，量身定做產品特性、服務模式和臨床支援。

美洲、歐洲、中東和非洲以及亞太地區的區域動態和細微的市場接受模式將決定差異化的市場進入和成長策略。

區域動態影響技術採納曲線、報銷格局和投資重點，為在美洲、歐洲、中東和非洲以及亞太地區營運的相關人員創造了不同的機會和挑戰。在美洲，支付方模式和大型綜合醫療系統正在推動對能夠顯著改善醫療服務流程的高通量解決方案的需求，而區域卓越中心和研究網路則正在加速早期臨床應用和通訊協定標準化。資金的取得和整合的採購結構正在簡化採購流程，同時更加重視可驗證的成果。

由於法規環境和報銷機制的差異，歐洲、中東和非洲的醫療技術應用模式呈現出多元化的特徵。有些國家採用集中式的國家體系，而有些國家則採用較細分的市場，這種差異影響供應商進入市場和服務交付的方式。相較之下，亞太地區的特點是產能快速擴張、對先進影像處理基礎設施的投資不斷增加以及國內製造能力的提升，這些因素都會影響價格和供應彈性。在一些市場，人口結構變化和慢性病負擔的加重正在推動對精準診斷的需求，而法規核准流程則影響臨床整合的步伐。

認知到這些區域差異有助於制定量身定做的打入市場策略、本地證據產生以及反映報銷慣例和臨床網路成熟度的服務模式。

關鍵的企業級策略結合了臨床夥伴關係、卓越服務和生態系統整合，以確保在混合成像領域獲得永續的競爭優勢。

混合成像領域的競爭格局不僅取決於系統效能，還取決於臨床夥伴關係、售後支援和生態系統整合。主要企業正透過投資合作研究計畫、多中心檢驗研究和培訓計劃，降低臨床應用門檻，並與關鍵意見領袖建立長期合作關係。與放射性藥物開發商和軟體供應商的策略聯盟日益普遍，從而能夠提供涵蓋成像硬體和示踪劑流程的捆綁式解決方案。

卓越的服務也是一項差異化優勢，能夠提供可預測的維護、快速的零件供應和強大的遠距離診斷服務的公司，可以提高設備的運轉率和客戶滿意度。商業模式也從獨立的資本銷售轉向以結果為導向的管理式服務協議轉變，使供應商的激勵機制與臨床應用和病患療效保持一致。此外，檢測器技術、影像重建演算法和示蹤劑化學的獎勵有助於提升競爭地位，而靈活的部署模式和資金籌措方案則有助於應對不同醫療環境中的預算限制。

能夠平衡技術創新、務實服務提供和臨床醫生參與的市場參與企業，將更有利於贏得長期合約、加入臨床網路並影響護理通訊協定。

為供應商和醫療服務提供者提供切實可行的建議，以最佳化產品設計、供應鏈彈性、商業化模式和臨床參與，從而實現混合成像的成功。

行業領導者應採取多管齊下的方法，使產品開發、商業化和臨床應用與不斷變化的醫療保健系統優先事項保持一致。首先，應優先考慮模組化系統結構和可互通的軟體平台，以便於升級並與電子健康記錄和腫瘤資訊系統整合。這將降低客戶續訂成本，並透過利用現有的數位化工作流程來加速臨床應用。其次，與其僅僅關注技術性能指標，不如投資於透過合作測試和真實世界研究來產生臨床證據，以證明其對診斷信心、患者管理和診療路徑的影響。

第三，我們將透過供應商網路多元化、建立區域服務中心以及探索近岸製造方案來增強供應鏈韌性，從而降低關稅和物流風險。第四，我們將發展靈活的商業模式，包括管理服務協議、績效基本契約和培訓套餐，以支援向醫院、診斷中心和研發機構的大規模部署。第五，我們將與放射性藥物開發公司和人工智慧分析提供者建立策略夥伴關係，以開發解決示蹤劑供應、定量成像和決策支援的整合解決方案。

最後，透過參與以臨床醫生為中心的教育和變革管理計劃，支持通訊協定標準化、跨部門協作以及將混合成像見解有效整合到治療決策中，這些綜合行動將使組織能夠將技術能力轉化為永續的臨床和商業性價值。

採用穩健的混合方法研究途徑，結合一手和二手研究以及嚴格的三角驗證，以確保獲得基於證據的混合影像學研究結果。

本研究整合了第一手資料和二手資料，並對臨床和政策發展進行了結構化回顧，以確保研究檢驗的平衡。第一手資料包括對臨床醫生、放射科管理人員、採購負責人和技術專家的深度訪談，從而獲得關於臨床工作流程、採購標準和服務期望的第一手觀點。二手資料包括同行評審的臨床研究、監管指南和公開的政策分析，這些資料描述了技術採納和報銷的動態。

透過嚴格的檢驗流程，將定量和定性資料進行三角驗證，該流程包括將訪談見解與已記錄的臨床方案和供應商服務內容進行交叉比對。利用已記錄的臨床用例和通訊協定標準化工作，對技術類型和應用領域進行了比較分析。調查方法的局限性包括依賴已發表的證據以及相關人員是否願意討論商業性細節。為了彌補這些不足，分析著重於總結和匿名化的見解，並在證據有限的情況下採用保守的解釋。

在整個研究過程中，我們始終遵守倫理考量和資料管治通訊協定，並由多學科專家審查研究結果，以確保其臨床和操作有效性。

簡明扼要的結論重點闡述了將混合成像創新轉化為可衡量的臨床和系統級價值所需的策略機會和營運要務。

混合影像代表診斷醫學的策略曲折點，它將技術創新與臨床工作流程和醫療保健系統目標連結起來。影像方式的融合、分析工具的日益成熟以及放射性藥物組合的不斷發展，為提高診斷特異性、實現治療方案個體化以及增強臨床決策能力創造了機會。同時，政策和供應鏈的變化凸顯了製定具有韌性的商業策略和靈活的部署模式的必要性，以適應成本結構和法規環境的變化。

價值鏈上的各相關人員迫切需要透過協作式證據產生、有針對性的臨床項目以及支持永續利用的服務模式，將技術能力轉化為可衡量的臨床價值。透過將產品開發與臨床醫生的需求相結合，並建立持久的營運支持，各機構可以確保其混合成像資產在患者管理和系統效率方面帶來顯著的改進。要充分發揮混合成像在現代醫療保健中的潛力，需要對證據、基礎設施和夥伴關係進行協同投資。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 透過將人工智慧驅動的重建演算法整合到PET/MRI中來提高診斷準確性
  • 可攜式混合成像設備的進步使得照護現場腫瘤評估成為可能。
  • PET/CT系統採用數位PET檢測器來降低輻射劑量並提高影像品質。
  • 全身PET掃描儀的出現，為研究提供了全面的代謝和功能性影像方法。
  • 擴展頻譜混合影像技術，結合PET、SPECT、CT和MRI，用於個人化治療計畫。
  • 透過開發與PET結合的造影MRI序列，實現同步解剖和代謝成像。
  • 實施雲端基礎的影像分析平台，用於混合影像資料共用和遠端協作

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 混合成像市場（依技術類型分類）

  • PET-CT
  • PET-MRI
  • SPECT-CT

9. 混合成像市場（依銷售管道分類）

  • 直銷
  • 經銷商

第10章 混合成像市場（依應用分類）

  • 心臟病學
    • 心肌灌注
    • 生存能力
  • 感染疾病
    • 感染區域的成像
    • 發炎成像
  • 神經病學
    • 癲癇
    • 神經退化
  • 腫瘤學
    • 造血系統惡性腫瘤
    • 固態腫瘤

第11章 混合成像市場（依最終用戶分類）

  • 診斷中心
  • 醫院
  • 研究所

第12章 混合影像市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 混合影像市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國混合影像市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Siemens Healthineers AG
    • GE HealthCare Technologies Inc.
    • Koninklijke Philips NV
    • Canon Medical Systems Corporation
    • Fujifilm Holdings Corporation
    • Hitachi, Ltd.
    • Shimadzu Corporation
    • United Imaging Healthcare Co., Ltd.
    • Neusoft Medical Systems Co., Ltd.
    • Spectrum Dynamics Medical Ltd.
Product Code: MRR-0360AB17DFF6

The Hybrid Imaging Market is projected to grow by USD 13.72 billion at a CAGR of 6.88% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 8.05 billion
Estimated Year [2025] USD 8.60 billion
Forecast Year [2032] USD 13.72 billion
CAGR (%) 6.88%

An authoritative introduction to the hybrid imaging environment emphasizing clinical drivers, technology convergence, and strategic priorities for healthcare stakeholders

Hybrid imaging is at the intersection of converging technologies, shifting clinical priorities, and evolving health system imperatives. Over recent years clinicians and technology developers have increasingly integrated anatomical and molecular modalities to improve diagnostic specificity and therapeutic monitoring, driving a focus on patient-centric workflows and precision medicine. This introduction outlines the core drivers, stakeholder expectations, and the strategic questions that decision-makers should prioritize when evaluating the hybrid imaging landscape.

Adoption patterns are influenced by the need for higher diagnostic confidence in complex indications, greater operational efficiency across imaging suites, and the pursuit of quantifiable outcomes that support reimbursement. Simultaneously, technological innovations in detector design, image fusion, and radiopharmaceutical development are enabling novel clinical use cases. As a result, providers are assessing capital acquisition strategies in the context of long-term clinical programs rather than single-use investments.

Clinicians and administrators must balance capital intensity with potential gains in diagnostic throughput, reduced downstream procedures, and improved patient management. Consequently, strategy conversations should integrate clinical pathways, vendor partnerships, and training programs to ensure that hybrid imaging assets deliver sustained value across the care continuum.

How technological convergence, regulatory recalibration, and supply chain realignment are jointly redefining value propositions in hybrid imaging for care providers and manufacturers

The hybrid imaging landscape is experiencing transformative shifts driven by technological convergence, regulatory evolution, and changing care delivery models. Recent years have seen the maturation of hybrid modalities that combine functional and structural imaging to deliver richer diagnostic context, while software advances in image processing and AI have begun to enhance diagnostic confidence and workflow efficiency. Parallel to these technical developments, regulatory frameworks and payer policies are adapting to evidence generated from hybrid studies, prompting manufacturers and clinical investigators to design trials that demonstrate meaningful clinical endpoints.

Supply chain realignment and component sourcing strategies are reshaping procurement and manufacturing decisions, encouraging modular designs and closer collaboration between system integrators and radiopharmaceutical suppliers. Clinical practice is also evolving; multidisciplinary teams are increasingly relying on hybrid imaging to inform personalized treatment plans, particularly in oncology and neurology, where molecular signatures guide therapeutic choices. Taken together, these shifts are not incremental but systemic: they redefine value propositions from purely hardware-centric to integrated clinical solutions encompassing devices, tracers, analytics, and service models.

Assessing the cumulative implications of 2025 tariff adjustments on sourcing, service continuity, and total cost of ownership across hybrid imaging value chains

Policy changes affecting cross-border trade and component tariffs have introduced new considerations for manufacturers, distributors, and health systems that rely on global supply chains. The cumulative impact of tariff adjustments in 2025 has altered cost structures for core subsystems, peripheral components, and radiopharmaceutical logistics, prompting stakeholders to reassess sourcing strategies and contractual terms with suppliers. In response, many organizations have explored nearshoring, diversified vendor bases, and longer-term procurement agreements to mitigate exposure to future trade policy volatility.

Clinicians and hospital finance teams are experiencing indirect effects through slower delivery timelines for capital equipment and increased lead times for replacement parts, which can influence equipment uptime and scheduling. Distributors and service providers have had to revise warranty terms and service-level agreements to accommodate changed cost bases, while manufacturers are reconsidering global production footprints to protect margins without compromising regulatory compliance and quality control.

Importantly, the tariff-driven environment has accelerated discussions about total cost of ownership, emphasizing maintenance, training, and clinical utilization as critical levers to preserve value. For stakeholders focused on long-term programs, the immediate policy-driven cost pressures have underscored the importance of contractual flexibility, collaborative supply relationships, and scenario planning to maintain continuity of care delivery and technology deployment.

Deep segmentation insights revealing how technology type, sales channels, clinical applications, and end-user profiles jointly determine hybrid imaging adoption and value realization

A nuanced understanding of segmentation clarifies where clinical demand, procurement pathways, and technology preferences intersect, shaping commercialization and deployment strategies. When evaluating technology types, clinicians and administrators differentiate offerings across PET-CT, PET-MRI, and SPECT-CT, each delivering distinct advantages in sensitivity, soft-tissue contrast, and operational footprint; these differences influence capital allocation, clinical protocols, and tracer utilization. Sales channels also matter: choices between direct sales engagements and distributor relationships affect contract flexibility, aftermarket support, and regional reach, with implications for service coverage and training programs.

Application-focused segmentation reveals how diagnostic priorities drive modality selection and protocol development. Cardiology applications, including myocardial perfusion and viability studies, demand consistent quantitative performance and streamlined workflows to support high-throughput cardiac programs. Infectious disease imaging, broken down into infection site imaging and inflammation imaging, requires flexible tracer options and rapid imaging timelines to inform acute care decisions. Neurology applications such as epilepsy and neurodegenerative evaluations benefit from high-resolution molecular mapping and standardized interpretation frameworks. Oncology practices, spanning hematologic malignancies and solid tumors, rely heavily on precise staging and response assessment to optimize therapeutic sequencing.

End-user profiles determine procurement cycles and utilization models, with diagnostic centers often prioritizing throughput and referral networks, hospitals emphasizing integrated care pathways and multidisciplinary access, and research institutes focusing on protocol flexibility and tracer development. Understanding how these dimensions interact enables tailored commercial strategies that align product features, service models, and clinical support with the distinct needs of each segment.

Regional dynamics and nuanced adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate differentiated market entry and growth strategies

Regional dynamics shape adoption curves, reimbursement landscapes, and investment priorities, creating differentiated opportunities and constraints for stakeholders operating across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, payer models and large integrated health systems drive demand for high-throughput solutions that demonstrate clear care pathway improvements, while regional centers of excellence and research networks accelerate early clinical adoption and protocol standardization. Access to capital and consolidated purchasing structures can streamline procurement but also increase emphasis on demonstrable outcomes.

In Europe, Middle East & Africa, heterogeneous regulatory environments and reimbursement structures create a mosaic of adoption patterns; centralized national systems in some countries contrast with more fragmented markets in others, affecting how vendors approach market entry and service delivery. Regional health priorities, such as oncology networks and neurology centers, guide investment in hybrid capabilities and radiopharmaceutical access. By contrast, the Asia-Pacific region is characterized by rapid capacity expansion, increasing investments in advanced imaging infrastructure, and growing domestic manufacturing capabilities that influence pricing and supply resilience. Demographic trends and rising chronic disease burdens in several markets expedite demand for precision diagnostics, while varying regulatory timelines shape the pace of clinical integration.

Recognizing these regional distinctions supports tailored go-to-market strategies, localized evidence generation, and service models that reflect reimbursement realities and the maturity of clinical networks.

Critical company-level strategies that combine clinical partnerships, service excellence, and ecosystem integration to secure durable competitive advantage in hybrid imaging

Competitive landscapes in hybrid imaging are defined not only by system performance but also by clinical partnerships, aftermarket support, and ecosystem integration. Leading organizations are investing in collaborative research programs, multi-center validation studies, and training initiatives that lower barriers to clinical adoption and create durable relationships with key opinion leaders. Strategic alliances with radiopharmaceutical developers and software providers are increasingly common, enabling bundled solutions that address both imaging hardware and tracer pipelines.

Service excellence is another differentiator; companies that provide predictable maintenance, rapid parts availability, and robust remote diagnostics enhance equipment uptime and customer satisfaction. Commercial models are also evolving from standalone capital sales toward outcome-oriented service contracts and managed service agreements that align vendor incentives with clinical utilization and patient outcomes. Additionally, intellectual property in detector technology, image reconstruction algorithms, and tracer chemistry contributes to competitive positioning, while flexible deployment models and financing options help address budgetary constraints in diverse healthcare settings.

Market participants that balance technological innovation with pragmatic service delivery and clinician engagement are better positioned to capture long-term contracts, participate in clinical networks, and influence care protocols.

Actionable recommendations for vendors and providers to optimize product design, supply resilience, commercialization models, and clinical engagement for hybrid imaging success

Industry leaders should adopt a multi-pronged approach that aligns product development, commercialization, and clinical engagement with evolving health system priorities. First, prioritize modular system architectures and interoperable software platforms to facilitate upgrades and integration with electronic health records and oncology information systems. This reduces refresh costs for customers and accelerates clinical adoption by leveraging existing digital workflows. Second, invest in clinical evidence generation through collaborative trials and real-world studies that demonstrate impact on diagnostic confidence, patient management, and care pathways rather than focusing solely on technical performance metrics.

Third, strengthen supply resilience by diversifying supplier networks, establishing regional service hubs, and exploring nearshore manufacturing options to mitigate tariff and logistics risks. Fourth, develop flexible commercial models including managed service agreements, outcome-based contracts, and training bundles that support scalable deployments across hospitals, diagnostic centers, and research institutes. Fifth, build strategic partnerships with radiopharmaceutical developers and AI analytics providers to offer integrated solutions that address tracer availability, quantitative imaging, and decision support.

Finally, commit to clinician-focused education and change management programs that support protocol standardization, cross-disciplinary collaboration, and the effective translation of hybrid imaging insights into treatment decisions. These combined actions will help organizations convert technological capabilities into sustainable clinical and commercial value.

A robust mixed-methods research approach combining primary stakeholder interviews, secondary clinical literature, and rigorous triangulation to ensure evidence-based hybrid imaging insights

This research synthesizes primary interviews, secondary literature, and a structured review of clinical and policy developments to ensure balanced and validated findings. Primary research includes in-depth interviews with clinicians, radiology administrators, procurement leaders, and technical specialists who provide firsthand perspectives on clinical workflows, purchasing criteria, and service expectations. Secondary inputs encompass peer-reviewed clinical studies, regulatory guidance, and publicly available policy analyses that contextualize technology adoption and reimbursement dynamics.

Quantitative and qualitative data were triangulated through a rigorous validation process that included cross-referencing interview insights with documented clinical protocols and supplier service offerings. Comparative analysis of technology types and application areas was performed using documented clinical use cases and protocol standardization efforts. Limitations of the methodology include reliance on available published evidence and stakeholder willingness to discuss commercial specifics; to mitigate these constraints, the analysis emphasizes aggregated and anonymized insights and applies conservative interpretations where evidence was limited.

Ethical considerations and data governance protocols were observed throughout the research process, and findings were reviewed by multidisciplinary experts to ensure clinical plausibility and operational relevance.

A concise conclusion underscoring the strategic opportunity and operational imperatives required to translate hybrid imaging innovations into measurable clinical and system-level value

The synthesis presented here emphasizes that hybrid imaging represents a strategic inflection point for diagnostic medicine, connecting technological innovation with clinical workflows and health system objectives. The convergence of modalities, maturation of analytic tools, and evolving radiopharmaceutical portfolios create opportunities to improve diagnostic specificity, personalize treatment pathways, and enhance clinical decision-making. At the same time, policy and supply chain shifts underscore the need for resilient commercial strategies and flexible deployment models that can adapt to changing cost structures and regulatory environments.

For stakeholders across the value chain, the imperative is to translate technical capabilities into measurable clinical value through collaborative evidence generation, targeted clinical programs, and service models that support sustained utilization. By aligning product development with clinician needs and building durable operational support, organizations can ensure that hybrid imaging assets deliver meaningful improvements in patient management and system efficiencies. The path forward requires coordinated investments in evidence, infrastructure, and partnerships to fully realize the promise of hybrid imaging in modern healthcare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven reconstruction algorithms in PET/MRI for enhanced diagnostic precision
  • 5.2. Advancements in portable hybrid imaging devices enabling point-of-care oncology assessments
  • 5.3. Adoption of digital PET detectors in PET/CT systems to reduce radiation dose and improve image quality
  • 5.4. Emergence of total-body PET scanners for comprehensive metabolic and functional imaging in research
  • 5.5. Expansion of multispectral hybrid imaging combining PET, SPECT, CT and MRI for personalized treatment planning
  • 5.6. Development of contrast-agent free MRI sequences integrated with PET for simultaneous anatomical and metabolic mapping
  • 5.7. Implementation of cloud-based image analysis platforms for hybrid imaging data sharing and remote collaboration

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hybrid Imaging Market, by Technology Type

  • 8.1. Pet-Ct
  • 8.2. Pet-Mri
  • 8.3. Spect-Ct

9. Hybrid Imaging Market, by Sales Channel

  • 9.1. Direct Sales
  • 9.2. Distributors

10. Hybrid Imaging Market, by Application

  • 10.1. Cardiology
    • 10.1.1. Myocardial Perfusion
    • 10.1.2. Viability
  • 10.2. Infectious Diseases
    • 10.2.1. Infection Site Imaging
    • 10.2.2. Inflammation Imaging
  • 10.3. Neurology
    • 10.3.1. Epilepsy
    • 10.3.2. Neurodegenerative
  • 10.4. Oncology
    • 10.4.1. Hematologic Malignancies
    • 10.4.2. Solid Tumors

11. Hybrid Imaging Market, by End User

  • 11.1. Diagnostic Centers
  • 11.2. Hospitals
  • 11.3. Research Institutes

12. Hybrid Imaging Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Hybrid Imaging Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Hybrid Imaging Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Siemens Healthineers AG
    • 15.3.2. GE HealthCare Technologies Inc.
    • 15.3.3. Koninklijke Philips N.V.
    • 15.3.4. Canon Medical Systems Corporation
    • 15.3.5. Fujifilm Holdings Corporation
    • 15.3.6. Hitachi, Ltd.
    • 15.3.7. Shimadzu Corporation
    • 15.3.8. United Imaging Healthcare Co., Ltd.
    • 15.3.9. Neusoft Medical Systems Co., Ltd.
    • 15.3.10. Spectrum Dynamics Medical Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HYBRID IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HYBRID IMAGING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HYBRID IMAGING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HYBRID IMAGING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HYBRID IMAGING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HYBRID IMAGING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HYBRID IMAGING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HYBRID IMAGING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HYBRID IMAGING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HYBRID IMAGING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HYBRID IMAGING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HYBRID IMAGING MARKET SIZE, BY SPECT-CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HYBRID IMAGING MARKET SIZE, BY SPECT-CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HYBRID IMAGING MARKET SIZE, BY SPECT-CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HYBRID IMAGING MARKET SIZE, BY SPECT-CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HYBRID IMAGING MARKET SIZE, BY SPECT-CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HYBRID IMAGING MARKET SIZE, BY SPECT-CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HYBRID IMAGING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HYBRID IMAGING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HYBRID IMAGING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HYBRID IMAGING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HYBRID IMAGING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HYBRID IMAGING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HYBRID IMAGING MARKET SIZE, BY MYOCARDIAL PERFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HYBRID IMAGING MARKET SIZE, BY MYOCARDIAL PERFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HYBRID IMAGING MARKET SIZE, BY MYOCARDIAL PERFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HYBRID IMAGING MARKET SIZE, BY MYOCARDIAL PERFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HYBRID IMAGING MARKET SIZE, BY MYOCARDIAL PERFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HYBRID IMAGING MARKET SIZE, BY MYOCARDIAL PERFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HYBRID IMAGING MARKET SIZE, BY VIABILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HYBRID IMAGING MARKET SIZE, BY VIABILITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HYBRID IMAGING MARKET SIZE, BY VIABILITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HYBRID IMAGING MARKET SIZE, BY VIABILITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HYBRID IMAGING MARKET SIZE, BY VIABILITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HYBRID IMAGING MARKET SIZE, BY VIABILITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTION SITE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTION SITE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTION SITE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTION SITE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTION SITE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTION SITE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFLAMMATION IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFLAMMATION IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFLAMMATION IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFLAMMATION IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFLAMMATION IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFLAMMATION IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HYBRID IMAGING MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HYBRID IMAGING MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HYBRID IMAGING MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HYBRID IMAGING MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HYBRID IMAGING MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HYBRID IMAGING MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEURODEGENERATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEURODEGENERATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEURODEGENERATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEURODEGENERATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HYBRID IMAGING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HYBRID IMAGING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HYBRID IMAGING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HYBRID IMAGING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HYBRID IMAGING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HYBRID IMAGING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HYBRID IMAGING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HYBRID IMAGING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HYBRID IMAGING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HYBRID IMAGING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HYBRID IMAGING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HYBRID IMAGING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HYBRID IMAGING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HYBRID IMAGING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HYBRID IMAGING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HYBRID IMAGING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HYBRID IMAGING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HYBRID IMAGING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HYBRID IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HYBRID IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HYBRID IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HYBRID IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HYBRID IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HYBRID IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HYBRID IMAGING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HYBRID IMAGING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS HYBRID IMAGING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS HYBRID IMAGING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL HYBRID IMAGING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL HYBRID IMAGING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. GCC HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GCC HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GCC HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. GCC HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. GCC HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. GCC HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. GCC HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 314. GCC HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 315. GCC HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 316. GCC HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 317. GCC HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 318. GCC HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 319. GCC HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 320. GCC HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 321. GCC HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 322. GCC HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 323. GCC HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. GCC HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 340. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 343. BRICS HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 344. BRICS HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 345. BRICS HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. BRICS HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. BRICS HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 348. BRICS HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 349. BRICS HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 350. BRICS HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 351. BRICS HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 352. BRICS HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 353. BRICS HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 354. BRICS HYB